Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Improving the care and understanding the complications of antineutrophil cytoplasmic antibody vasculitis

FY 2018-19

Summary
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is a rare inflammatory disease which affects small blood vessels. When left untreated, it leads to permanent organ failure, in particular kidney failure, and death. Treatments for ANCA-associated vasculitis (AAV) suppress the immune system to limit organ damage. While these have improved patient survival, they are associated with significant side effects, particularly infections. Also, AAV leads to chronic kidney disease (CKD) in most patients, a strong risk factor for cardiovascular diseases. It is thought that patients with AAV end up dying more from infections and cardiovascular disease than from the vasculitis itself. This leads to difficult decisions trying to balance between treating AAV and avoiding serious side effects, particularly in the elderly who are more prone to infections and cardiovascular events. Unfortunately, being a rare disease, there is limited real-world data on the current state of AAV which affects physicians’ ability to inform patients on the risks associated with their disease and its treatment. Major society guidelines have recognized the important knowledge gaps in the long-term management of patients with AAV with immunosuppression and the need for studies properly evaluating the long-term outcomes of patients with AAV. We propose a series of studies to determine the risks for infections, hospitalizations, adverse cardiovascular events, end-stage kidney disease and death among patients with AAV and the risk for adverse outcomes in patients ?66 years old treated for AAV. Our project will inform on the current state of AAV within Ontario and provide valuable information on the long-term prognosis of AAV, as well as the risks associated with immunosuppressive
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406352
Name
Massicotte-Azarniouch David
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Improving the care and understanding the complications of antineutrophil cytoplasmic antibody vasculitis
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anca; Cardiovascular Disease; Chronic Kidney Disease; Epidemiology; Glomerulonephritis; Infection; Vasculitis
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is a rare inflammatory disease which affects small blood vessels. When left untreated, it leads to permanent organ failure, in particular kidney failure, and death. Treatments for ANCA-associated vasculitis (AAV) suppress the immune system to limit organ damage. While these have improved patient survival, they are associated with significant side effects, particularly infections. Also, AAV leads to chronic kidney disease (CKD) in most patients, a strong risk factor for cardiovascular diseases. It is thought that patients with AAV end up dying more from infections and cardiovascular disease than from the vasculitis itself. This leads to difficult decisions trying to balance between treating AAV and avoiding serious side effects, particularly in the elderly who are more prone to infections and cardiovascular events. Unfortunately, being a rare disease, there is limited real-world data on the current state of AAV which affects physicians’ ability to inform patients on the risks associated with their disease and its treatment. Major society guidelines have recognized the important knowledge gaps in the long-term management of patients with AAV with immunosuppression and the need for studies properly evaluating the long-term outcomes of patients with AAV. We propose a series of studies to determine the risks for infections, hospitalizations, adverse cardiovascular events, end-stage kidney disease and death among patients with AAV and the risk for adverse outcomes in patients ?66 years old treated for AAV. Our project will inform on the current state of AAV within Ontario and provide valuable information on the long-term prognosis of AAV, as well as the risks associated with immunosuppressive
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Massicotte-Azarniouch, David
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~